Who are the top shareholders of the Aarti Drugs?

The top shareholders of Aarti Drugs include promoter Prakash Moreshwar Patil with 9.32%, mutual funds with 8.75%, foreign institutional investors at 2.25%, and the DSP Small Cap Fund as the largest public shareholder at 7.13%. Individual investors collectively own 23.51% of the company.

The top shareholders of Aarti Drugs include the promoters, who hold the majority of the shares. The promoter with the highest holding is Prakash Moreshwar Patil, with a stake of 9.32%. Additionally, mutual funds hold 8.75% of the shares across seven schemes, while foreign institutional investors (FIIs) account for 2.25% through 80 different entities. The highest public shareholder is the DSP Small Cap Fund, which holds 7.13%. Individual investors collectively own 23.51% of the company.

how big is Aarti Drugs?

As of Jun 06, Aarti Drugs Ltd has a market capitalization of 4,247.40 Cr, with recent net sales of 2,387.03 Cr and a net profit of 168.16 Cr over the last four quarters.

Market Cap: Aarti Drugs Ltd has a market capitalization of 4,247.40 Cr and is classified as a Small Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,387.03 Cr, while the sum of Net Profit for the same period is 168.16 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar 24. Shareholder's Funds are reported at 1,281.55 Cr, and Total Assets amount to 2,432.36 Cr.

What is the bonus history of the Aarti Drugs?

Aarti Drugs has a history of issuing bonuses to shareholders, with the most recent being a 3:1 bonus announced on September 30, 2020, and a previous 1:1 bonus issued on March 25, 2015.

Aarti Drugs has a history of issuing bonuses to its shareholders. The most recent bonus was a 3:1 issue, which was announced with an ex-date of September 30, 2020, and a record date of October 1, 2020. Prior to that, the company issued a 1:1 bonus on March 25, 2015, with an ex-date of March 24, 2015. This indicates that Aarti Drugs has actively engaged in rewarding its shareholders through bonus shares over the years.

Has Aarti Drugs declared dividend?

Yes, Aarti Drugs Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of February 4, 2025. Despite fluctuations in total returns over various periods, the company has shown a strong recovery with an 87.91% total return over the past 5 years.

Aarti Drugs Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 04 Feb 25<BR><BR>Dividend Yield: 0.22%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Aarti Drugs experienced a price return of 1.63%, a dividend return of 0.22%, resulting in a total return of 1.85%.<BR><BR>Over the past year, the company had a price return of -5.97%, a dividend return of 0.19%, leading to a total return of -5.78%.<BR><BR>In the 2-year period, Aarti Drugs recorded a price return of 0.75%, a dividend return of 0.43%, culminating in a total return of 1.18%.<BR><BR>For the 3-year period, the company achieved a price return of 8.87%, a dividend return of 0.79%, resulting in a total return of 9.66%.<BR><BR>In the last 4 years, Aarti Drugs saw a price return of -39.02%, a dividend return of 0.57%, which led to a total return of -38.45%.<BR><BR>Over the past 5 years, the company experienced a significant price return of 85.85%, a dividend return of 2.06%, resulting in a total return of 87.91%.<BR><BR>Overall, Aarti Drugs has declared a dividend, and while the company has faced fluctuations in total returns over different periods, the recent 5-year performance indicates a strong recovery with substantial returns.

Who are the peers of the Aarti Drugs?

Aarti Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Gufic BioScience, RPG LifeScience, Morepen Labs, and Advanced Enzyme. Aarti Drugs has good management risk and capital structure but a below-average growth rate and the lowest 1-year return among its peers at -3.71%.

Peers: The peers of Aarti Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Gufic BioScience, RPG LifeScience, Morepen Labs, and Advanced Enzyme.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Gufic BioScience, RPG LifeScience, Advanced Enzyme, and the rest. Good management risk is found at Aarti Drugs, Divi's Lab., Torrent Pharma, and Morepen Labs. Average management risk is noted at Morepen Labs, while below average management risk is seen at RPG LifeScience and Guj. Themis Bio. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is observed at Divi's Lab., Torrent Pharma, Aarti Drugs, RPG LifeScience, Advanced Enzyme, and the rest. Average growth is noted at Gufic BioScience, while good growth is found at Morepen Labs. Capital structure is excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Gufic BioScience, RPG LifeScience, and the rest, while good capital structure is seen at Aarti Drugs and Torrent Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while Aarti Drugs has a 1-year return of -3.71%, which is significantly lower. The peer with the lowest 1-year return is Aarti Drugs at -3.71%. Additionally, Gufic BioScience, Advanced Enzyme, and RPG LifeScience have negative six-month returns.

Is Aarti Drugs overvalued or undervalued?

As of May 26, 2025, Aarti Drugs is considered undervalued with a PE ratio of 25.26 and a favorable valuation compared to peers like Sun Pharma and Divi's Lab, despite underperforming the Sensex over the past year but recently achieving a 1-month return of 11.43%.

As of 26 May 2025, Aarti Drugs has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, with a PE ratio of 25.26, an EV to EBITDA ratio of 16.91, and a ROE of 12.28%. In comparison to its peers, Aarti Drugs' valuation is more favorable than Sun Pharma, which is deemed expensive with a PE of 35.25, and Divi's Lab, categorized as very expensive with a PE of 79.33.<BR><BR>The company's performance metrics suggest it is positioned well within the pharmaceuticals and biotechnology sector. Notably, Aarti Drugs has a PEG ratio of 0.00, indicating potential for growth relative to its price. While the stock has underperformed the Sensex over the past year, its recent 1-month return of 11.43% outpaces the Sensex's 3.88%, reinforcing the attractiveness of its valuation.

When is the next results date for Aarti Drugs?

Aarti Drugs will announce its results on 18 July 2025.

Aarti Drugs will declare its results on 18 July 2025.

Who are in the management team of Aarti Drugs?

As of March 2023, the management team of Aarti Drugs includes Prakash M Patil (CMD), Rashesh C Gogri (MD), Harshit M Savla (Joint MD), and several other executive and independent directors responsible for the company's operations and strategy.

As of March 2023, the management team of Aarti Drugs includes the following members:<BR><BR>1. Prakash M Patil - CMD & Executive Director<BR>2. Rashesh C Gogri - ED / MD / Promoter<BR>3. Harshit M Savla - ED / Joint MD / Promoter<BR>4. Harit P Shah - ED & Wholetime Director<BR>5. Uday M Patil - WTD & Executive Director<BR>6. Narendra Jagannath Salvi - Non Executive Director<BR>7. Navin Chapshi Shah - Independent Non Executive Director<BR>8. Krishnacharya G Akamanchi - Independent Non Executive Director<BR>9. Priti Savla - Independent Non Executive Director<BR>10. Ankit Vikram Paleja - Independent Non Executive Director<BR>11. Bhaskar Narayan Thorat - Independent Non Executive Director<BR>12. Neha Gada - Independent Non Executive Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Aarti Drugs do?

Aarti Drugs Ltd is a leading manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals, established in 1984, with a market cap of INR 4,846 Cr and reported net sales of 6,768 Cr and net profit of 629 Cr for the quarter ending March 2025. The company has a P/E ratio of 28.00 and a dividend yield of 0.19%.

Overview:<BR>Aarti Drugs Ltd is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals in the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap company.<BR><BR>History:<BR>Incorporated in September 1984, Aarti Drugs Ltd has established itself as a market leader in APIs. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 6,768 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 629 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 4,846 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 28.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.19%<BR>- Debt Equity: 0.44<BR>- Return on Equity: 12.28%<BR>- Price to Book: 3.56<BR><BR>Contact Details:<BR>Address: Plot No N-198 MIDC Tarapur, Pamtembhi Village Palghar Tal Thane Maharashtra : 401506<BR>Tel: 91-22-24072249<BR>Email: investorrelations@aartidrugs.com<BR>Website: http://www.aartidrugs.com

Are Aarti Drugs latest results good or bad?

Aarti Drugs' latest results show a 28.2% increase in Profit After Tax to Rs 53.91 crore, indicating improved profitability. However, concerns arise from a significant decline in cash reserves and net sales, suggesting operational challenges that need to be addressed for future growth.

Aarti Drugs' latest results present a mixed picture. On one hand, the company reported a Profit After Tax (PAT) of Rs 53.91 crore for the quarter ending June 2025, which reflects a strong growth of 28.2% compared to the average PAT from the previous four quarters. This indicates an improvement in profitability and suggests that the company is managing to enhance its earnings despite a competitive market.<BR><BR>However, there are concerns regarding the company's cash position, as cash and cash equivalents have fallen to Rs 7.56 crore, the lowest in the last three years. This decline points to a deterioration in short-term liquidity, which could pose challenges in the future.<BR><BR>Additionally, the company experienced a decline in net sales and consolidated net profit on a quarter-over-quarter basis, with net sales dropping by 12.74% and consolidated net profit decreasing by 14.24%. These trends indicate some operational challenges that Aarti Drugs is currently facing.<BR><BR>Overall, while the growth in PAT is a positive sign, the decline in sales and cash position raises some red flags. The stock has received a 'Buy' recommendation from MarketsMOJO, suggesting that there is still confidence in the company's potential, but addressing liquidity issues will be crucial for sustaining future growth.

How has been the historical performance of Aarti Drugs?

Aarti Drugs has seen a decline in net sales and total operating income from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025, while profit after tax slightly increased from INR 166.36 crore to INR 168.10 crore during the same period. Total assets and liabilities rose, but cash flow from operating activities decreased significantly.

Answer:<BR>The historical performance of Aarti Drugs shows fluctuations in various financial metrics over the years.<BR><BR>Breakdown:<BR>Aarti Drugs' net sales have experienced a decline from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025. The total operating income followed a similar trend, decreasing from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025. The total expenditure, excluding depreciation, also decreased from INR 2,410.45 crore in March 2023 to INR 2,099.97 crore in March 2025, contributing to an operating profit (PBDIT) of INR 303.42 crore in March 2025, down from INR 307.79 crore in March 2023. Profit before tax showed a decline from INR 224.18 crore in March 2023 to INR 211.77 crore in March 2025, while profit after tax slightly increased from INR 166.36 crore in March 2023 to INR 168.10 crore in March 2025. The consolidated net profit also saw a minor increase from INR 166.31 crore in March 2023 to INR 168.16 crore in March 2025. On the balance sheet, total assets rose from INR 2,421.40 crore in March 2023 to INR 2,574.68 crore in March 2025, while total liabilities increased from INR 2,421.40 crore to INR 2,574.68 crore during the same period. Cash flow from operating activities decreased from INR 358.00 crore in March 2024 to INR 244.00 crore in March 2025, and the closing cash and cash equivalents dropped from INR 6.00 crore in March 2024 to INR 4.00 crore in March 2025.

Should I buy, sell or hold Aarti Drugs?

Is Aarti Drugs technically bullish or bearish?

As of November 28, 2025, the market trend is neutral with mixed signals, showing a sideways movement influenced by conflicting indicators, including mildly bearish weekly MACD and Bollinger Bands, alongside mildly bullish daily moving averages.

As of 28 November 2025, the technical trend has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating conflicting momentum. The Bollinger Bands are bearish on both weekly and monthly time frames, suggesting downward pressure. Daily moving averages are mildly bullish, providing some support. The KST is mildly bearish on the weekly and bearish on the monthly, while the Dow Theory shows a similar pattern with a mildly bearish weekly stance and mildly bullish monthly. Overall, the indicators reflect a lack of clear direction, reinforcing the sideways trend.

Which are the latest news on Aarti Drugs?

Why is Aarti Drugs falling/rising?

As of 05-Dec, Aarti Drugs Ltd's stock price is at Rs 405.00, down 0.81%, with significant declines over various time frames and reduced investor participation. Despite positive financial indicators, the stock's performance remains negative due to bearish market sentiment.

As of 05-Dec, Aarti Drugs Ltd's stock price is falling, currently at Rs 405.00, which reflects a decrease of Rs 3.3 or 0.81%. The stock has underperformed significantly over various time frames, with a 1-week decline of 4.80%, a 1-month drop of 19.56%, and a year-to-date decrease of 12.08%. Additionally, the stock has been on a consecutive decline for the last two days, with a total return loss of 1.36% during this period.<BR><BR>Investor participation has also diminished, as evidenced by a 40.01% drop in delivery volume compared to the 5-day average, indicating reduced trading interest. The stock is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals bearish sentiment.<BR><BR>Despite some positive financial indicators, such as a high return on capital employed (ROCE) of 15.44% and a low debt-to-equity ratio of 0.46, these factors have not been sufficient to counteract the negative price movements. The company's profits have increased by 30.7% over the past year, yet the stock has still generated a negative return of -11.05%. This discrepancy suggests that while the company's fundamentals may be improving, market sentiment and external factors are currently driving the stock price down.